Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs.
Martina MaritatiAlessandro TrentiniGregory MichelTiziana BelliniShawgi AlmugadamStefania HanauMarcello GovoniPierre MartyCarlo ContiniPublished in: Infection (2018)
We can speculate that exposure to rural areas appears to be a factor closely linked with the risk of developing Leishmania subclinical infection. A screening with molecular methods in patients with CIRD treated with BD living in these areas and monitoring Leishmania DNA during such therapies, would be mandatory to prevent delay in diagnosis should VL symptoms appear.